They are recombinant humanized monoclonal antibodies directed against IL-6 receptor (IL-6R), which competitively inhibit the binding of IL-6 to its receptor, thereby alleviating the symptoms of CRS [120]. The gene discussed is IL6; the disease is congenital rubella syndrome.